Business
Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
- A scientific-data oral presentation, two posters and a symposium presentation will highlight the clinical and research advantages of the company’s Afirma
About this update from Veracyte, Inc.
[{"type":"text","content":"\n- A scientific-data oral presentation, two posters and a symposium presentation will highlight the clinical and research advantages of the company’s Afirma molecular test and capabilities -\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting new data on the company’s Afirma test and capabilities will be presented at ENDO 2023, the annual meeting of The Endocrine Society, which is taking place June 15-18 in Chicago, Ill. Additionally, Veracyte’s medical director of Endocrinology, Joshua Klopper, M.D., will participate in a symposium panel discussion on the advantages of various molecular testing approaches to help personalize and improve care for people with potentially cancerous thyroid nodules.\n\n\n“The new data we will share at ENDO 2023 demonstrate Veracyte’s ongoing commitment to advancing the science around thyroid nodule management and cancer,” said Dr. Klopper. “They show how we are helping physicians further personalize treatment for their patients with thyroid nodules, while also helping researchers identify additional molecular characteristics of these nodules that could potentially provide clinically actionable prognostic information.”\n\n\nThe following abstracts will be presented at the ENDO 2023 meeting, with all presentations taking place at McCormick Place:\n\n\nTitle: Cytologic and Molecular Assessment of Isthmus Thyroid Nodules\nPresenter: Sina Jasim, M.D., M.P.H., Washington University in St. Louis\nAbstract: P85\nSession: Poster Session – Late Breaking Poster Abstracts\nDate/Time: June 15, 12:30 – 1:30 p.m. CT\nLocation: ENDO Expo Hall\n\n\nTitle: Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay\nPresenter: Priyanka Iyer, M.D., M.D. Anderson Cancer Center\nAbstract: P87\nSession: Poster Session - Late Breaking Poster Abstracts\nDate/Time: June 17, 1:00 – 2:00 p.m. CT\nLocation: ENDO Expo Hall\n\n\nTitle: mRNA Expression Based Tumor Behavior Prediction Models in Thyroid Nodules\nPresenter: Allan Golding, M.D., Memorial Healthcare System\nAbstract: OR32-03\nSession: Oral Presentation - Predicting Thyroid Malignancy: What Tools Do We Have?\nDate/Time: June 18, 8:30 – 8:45 a.m. CT\nLocation: Room W-176\n\n\nIn addition to the new data that will be shared during these presentations, Dr. Kl...